Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorporated

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Ligand Pharma, with a price target of $220.00. According...

Stifel Nicolaus Reaffirms Their Buy Rating on Ligand Pharma (LGND)

Oppenheimer analyst Trevor Allred maintained a Buy rating on Ligand Pharma today and set a price target of $250.00. The company’s shares opened tod...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	1 years
Ex-Dividend	Invalid Date	Pay Date	4/19/2007
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LGND	$199.23	+0.10%	264.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LGND	$199.23	+0.1%	264.60K
3
4
5
6

LGND

LGND

Dividend Overview

Dividend Yield History

Stock Price

TTM Dividend Payout

TTM Dividend Yield

Historical Yield Data

Recent Dividend History

Get Ligand Pharmaceuticals Incorporated Data in Excel

Get Ligand Pharmaceuticals Incorporated Data in Excel